

# Jordi Bruix

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7097626/publications.pdf>

Version: 2024-02-01

329  
papers

108,947  
citations

1046

113  
h-index

162

323  
g-index

355  
all docs

355  
docs citations

355  
times ranked

44345  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 593-604.	12.1	62
2	Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 283-292.e10.	4.4	94
3	Liver Imaging Reporting and Data System: Review of Pros and Cons. <i>Seminars in Liver Disease</i> , 2022, 42, 104-111.	3.6	2
4	First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials. <i>Liver Cancer</i> , 2022, 11, 75-84.	7.7	29
5	Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules. <i>Journal of Hepatology</i> , 2022, 76, 874-882.	3.7	17
6	BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. <i>Journal of Hepatology</i> , 2022, 76, 681-693.	3.7	1,495
7	HCC-neuroendocrine transition: Tumor plasticity under immunotherapy. <i>Gastroenterology</i> & <i>Hepatology</i> , 2022, , .	0.5	1
8	Early nivolumab addition to regorafenib in patients with hepatocellular carcinoma progressing under first-line therapy (GOING trial), interim analysis and safety profile.. <i>Journal of Clinical Oncology</i> , 2022, 40, 428-428.	1.6	6
9	ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS498-TPS498.	1.6	7
10	Reply to: "Correspondence on the BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update". <i>Journal of Hepatology</i> , 2022, 76, 1240-1241.	3.7	2
11	POLYETHYLENE-GLYCOL DRUG-ELUTING EMBOLIC MICROSPHERES LOADED WITH DOXORUBICIN FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA: FEASIBILITY, SAFETY AND PHARMACOKINETIC STUDY. <i>Journal of Vascular and Interventional Radiology</i> , 2022, , .	0.5	2
12	Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study. <i>Liver International</i> , 2022, 42, 1891-1901.	3.9	11
13	A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	8.6	17
14	Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with anti-VEGF/TKI and immunotherapy. <i>Hepatology</i> , 2022, 76, 1203-1218.	7.3	22
15	Portal hypertension may influence the registration of hypointensity of small hepatocellular carcinoma in the hepatobiliary phase in gadoteric acid MR. <i>Radiology and Oncology</i> , 2022, 56, 292-302.	1.7	0
16	Low Baseline Plasma L-Glutamine Concentration Identifies Hepatocellular Carcinoma Patients at High Risk of Developing Early Gastrointestinal Adverse Events during Sorafenib Treatment. <i>Gastrointestinal Disorders</i> , 2022, 4, 141-152.	0.8	0
17	Local and Regional Therapies for Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 73, 137-149.	7.3	69
18	Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 426.	3.7	4

#	ARTICLE	IF	CITATIONS
19	Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules $\leq$ 2 cm in cirrhotic patients. <i>European Radiology</i> , 2021, 31, 4794-4803.	4.5	8
20	Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice. <i>European Journal of Radiology</i> , 2021, 135, 109484.	2.6	20
21	Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity. <i>Oncotarget</i> , 2021, 12, 440-449.	1.8	1
22	Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity. <i>Cell Death and Disease</i> , 2021, 12, 555.	6.3	10
23	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. <i>Medicina Clínica (English Edition)</i> , 2021, 156, 463.e1-463.e30.	0.2	16
24	Assessing the impact of COVID-19 on liver cancer management (CERO-19). <i>JHEP Reports</i> , 2021, 3, 100260.	4.9	36
25	Endpoints in clinical trials for liver cancer and their value in evidence-based clinical decision making: An unresolved Gordian knot. <i>Journal of Hepatology</i> , 2021, 74, 1483-1488.	3.7	23
26	Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival. <i>Journal of Hepatology</i> , 2021, 75, 1154-1163.	3.7	9
27	Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs. <i>United European Gastroenterology Journal</i> , 2021, 9, 655-661.	3.8	2
28	Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types. <i>Cancer Management and Research</i> , 2021, Volume 13, 5523-5533.	1.9	6
29	Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study. <i>Liver Transplantation</i> , 2021, 27, 1767-1778.	2.4	19
30	Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2991-3001.	1.6	257
31	Systemic treatment of hepatocellular carcinoma: An EASL position paper. <i>Journal of Hepatology</i> , 2021, 75, 960-974.	3.7	217
32	Pancreatic Insufficiency in Patients Under Sorafenib Treatment for Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 263-270.	2.2	3
33	Immunotherapy for patients with hepatocellular carcinoma and chronic viral infections. <i>Journal of Hepatology</i> , 2021, , .	3.7	3
34	Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma. <i>European Radiology</i> , 2020, 30, 186-194.	4.5	25
35	Reply to: "The reported clear cut time association between interferon-free treatment and HCC is anything but clear cut". <i>Journal of Hepatology</i> , 2020, 72, 1036-1037.	3.7	1
36	Letter: are sorafenib-related adverse events associated with prolonged survival? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 192-192.	3.7	0

#	ARTICLE	IF	CITATIONS
37	Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2020, 24, 719-737.	2.1	29
38	Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials. <i>Liver International</i> , 2020, 40, 2476-2488.	3.9	6
39	Towards personalized screening for hepatocellular carcinoma: Still not there. <i>Journal of Hepatology</i> , 2020, 73, 1319-1321.	3.7	4
40	Hepatic epithelioid hemangioendothelioma: An international multicenter study. <i>Digestive and Liver Disease</i> , 2020, 52, 1041-1046.	0.9	13
41	International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis. <i>Liver International</i> , 2020, 40, 1467-1476.	3.9	15
42	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 557-588.	17.8	1,155
43	Does transient arterial-phase respiratory-motion-related artifact impact on diagnostic performance? An intra-patient comparison of extracellular gadolinium versus gadoxetic acid. <i>European Radiology</i> , 2020, 30, 6694-6701.	4.5	8
44	Evolving role of regorafenib for the treatment of advanced cancers. <i>Cancer Treatment Reviews</i> , 2020, 86, 101993.	7.7	61
45	Relationship between changes in the exon-recognition machinery and SLC22A1 alternative splicing in hepatocellular carcinoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165687.	3.8	8
46	Bespoken Nanoceria: An Effective Treatment in Experimental Hepatocellular Carcinoma. <i>Hepatology</i> , 2020, 72, 1267-1282.	7.3	37
47	Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models. <i>Cancers</i> , 2020, 12, 332.	3.7	13
48	Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.. <i>Journal of Clinical Oncology</i> , 2020, 38, 478-478.	1.6	93
49	Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. <i>Gut</i> , 2019, 68, 1065-1075.	12.1	195
50	Identification of Coding and Long Noncoding RNAs Differentially Expressed in Tumors and Preferentially Expressed in Healthy Tissues. <i>Cancer Research</i> , 2019, 79, 5167-5180.	0.9	38
51	Insights into the success and failure of systemic therapy for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 617-630.	17.8	132
52	Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. <i>American Journal of Transplantation</i> , 2019, 19, 3176-3184.	4.7	60
53	Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 482-491.	3.7	40
54	Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. <i>Journal of Hepatology</i> , 2019, 70, 874-884.	3.7	67

#	ARTICLE	IF	CITATIONS
55	Reply to: "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules" A response Journal of Hepatology, 2019, 71, 447-448.	3.7	0
56	Prospective evaluation of gadoxetic acid magnetic resonance for the diagnosis of hepatocellular carcinoma in newly detected nodules in cirrhosis. Liver International, 2019, 39, 1281-1291.	3.9	20
57	Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma. Gastroenterology, 2019, 156, 1731-1741.	1.3	160
58	Controversies in the management of hepatocellular carcinoma. JHEP Reports, 2019, 1, 17-29.	4.9	45
59	Diagnosis of Hepatic Nodules in Patients at Risk for Hepatocellular Carcinoma: LI-RADS Probability Versus Certainty. Gastroenterology, 2019, 156, 860-862.	1.3	11
60	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncology, The, 2018, 19, 682-693.	10.7	285
61	Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. European Journal of Radiology, 2018, 101, 72-81.	2.6	263
62	Lenvatinib: can a non-inferiority trial change clinical practice?. Lancet, The, 2018, 391, 1123-1124.	13.7	12
63	Hepatocellular carcinoma. Lancet, The, 2018, 391, 1301-1314.	13.7	3,878
64	Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. Journal of Hepatology, 2018, 69, 353-358.	3.7	270
65	Reply to: "Predictors of sorafenib benefit in patients with hepatocellular carcinoma" Journal of Hepatology, 2018, 68, 620-621.	3.7	0
66	Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events. Hepatology, 2018, 67, 612-622.	7.3	55
67	Benefits of laparoscopic liver resection in patients with hepatocellular carcinoma and portal hypertension: a case-matched study. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 2345-2354.	2.4	28
68	Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria). Liver Transplantation, 2018, 24, 369-379.	2.4	47
69	Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma. Oncotarget, 2018, 9, 16701-16717.	1.8	44
70	Locoregional versus systemic therapy "robust positive data remain elusive. Nature Reviews Clinical Oncology, 2018, 15, 537-538.	27.6	3
71	Liver Metastases From Gastric Adenocarcinoma Mimicking Multinodular Hepatocellular Carcinoma. Hepatology, 2018, 68, 2042-2044.	7.3	1
72	Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib.. Journal of Clinical Oncology, 2018, 36, 412-412.	1.6	40

#	ARTICLE	IF	CITATIONS
73	Systemic therapy for hepatocellular carcinoma: trial enrichment does not guarantee success. <i>Oncotarget</i> , 2018, 9, 33741-33742.	1.8	1
74	The impact of direct antiviral agents on the development and recurrence of hepatocellular carcinoma. <i>Liver International</i> , 2017, 37, 136-139.	3.9	31
75	Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them. <i>Journal of Hepatology</i> , 2017, 66, 1114-1117.	3.7	26
76	Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017, 389, 56-66.	13.7	2,771
77	Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 109, S149-S153.	4.0	18
78	Características clínicas del carcinoma hepatocelular en España. Comparación con el período 2008-2009 y análisis de las causas del diagnóstico fuera de cribado. <i>Estudio de 686 casos en 73 centros. Medicina Clínica</i> , 2017, 149, 61-71.	0.6	17
79	Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?. <i>Seminars in Liver Disease</i> , 2017, 37, 109-118.	3.6	73
80	Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 203-217.	17.8	304
81	Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers. <i>Medicina Clínica (English Edition)</i> , 2017, 149, 61-71.	0.2	4
82	Permissiveness of human hepatocellular carcinoma cell lines for hepatitis C virus entry and replication. <i>Virus Research</i> , 2017, 240, 35-46.	2.2	2
83	Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. <i>Journal of Hepatology</i> , 2017, 67, 999-1008.	3.7	465
84	Efficacy of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial according to alpha-fetoprotein (AFP) and c-Met levels as predictors of poor prognosis. <i>Journal of Clinical Oncology</i> , 2017, 35, 4078-4078.	1.6	12
85	Weak correlation of overall survival and time to progression in advanced hepatocellular carcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 233-233.	1.6	9
86	Role of drug-dependent transporter modulation on the chemosensitivity of cholangiocarcinoma. <i>Oncotarget</i> , 2017, 8, 90185-90196.	1.8	6
87	The success of regorafenib in hepatocellular carcinoma in a world of failures. Learnings for future developments. <i>Oncotarget</i> , 2017, 8, 106151-106152.	1.8	5
88	Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2017, 23, 2448.	3.3	10
89	Akt-mediated foxo1 inhibition is required for liver regeneration. <i>Hepatology</i> , 2016, 63, 1660-1674.	7.3	55
90	Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection. <i>Hepatology</i> , 2016, 63, 839-849.	7.3	101

#	ARTICLE	IF	CITATIONS
91	Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. <i>Journal of Hepatology</i> , 2016, 65, 719-726.	3.7	883
92	Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1923-1936.	1.8	15
93	Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 511.e1-511.e22.	0.2	2
94	Regorafenib and the RESORCE trial: a new second-line option for hepatocellular carcinoma patients. <i>Hepatic Oncology</i> , 2016, 3, 187-189.	4.2	5
95	Reply to "Direct antiviral agents and risk for hepatocellular carcinoma (HCC) early recurrence: Much ado about nothing". <i>Journal of Hepatology</i> , 2016, 65, 864-865.	3.7	6
96	Reply. <i>Hepatology</i> , 2016, 63, 1054-1055.	7.3	2
97	Treatment of Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2016, 34, 597-602.	1.9	72
98	Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. <i>Journal of Hepatology</i> , 2016, 64, 1090-1098.	3.7	567
99	Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2016, 150, 835-853.	1.3	1,365
100	Inheriting a Jewel: A Thrilling Challenge. <i>Seminars in Liver Disease</i> , 2016, 36, 003-004.	3.6	1
101	Tumor and plasma biomarker analysis from the randomized controlled phase II trial (RCT) of tivantinib in second-line hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 197-197.	1.6	3
102	Restoring miR122 in human stem-like hepatocarcinoma cells, prompts tumor dormancy through Smad-independent TGF- $\beta$ 2 pathway. <i>Oncotarget</i> , 2016, 7, 71309-71329.	1.8	27
103	Pattern of tumor progression in liver cancer: The missing partner in trial design. <i>Hepatology</i> , 2015, 62, 674-676.	7.3	10
104	Reply. <i>Hepatology</i> , 2015, 62, 978-979.	7.3	0
105	A Snapshot of the Effective Indications and Results of Surgery for Hepatocellular Carcinoma in Tertiary Referral Centers. <i>Annals of Surgery</i> , 2015, 262, e30.	4.2	23
106	Value of Transient Elastography Measured With Fibroscan in Predicting the Outcome of Hepatic Resection for Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2015, 261, e105.	4.2	8
107	Stabilization of LKB1 and Akt by neddylation regulates energy metabolism in liver cancer. <i>Oncotarget</i> , 2015, 6, 2509-2523.	1.8	69
108	SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 559-566.	1.6	479



#	ARTICLE	IF	CITATIONS
109	Authors'™ response to the letter: Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours or portal hypertension by Zhong<i> et al</i>. Gut, 2015, 64, 522-522.	12.1	5
110	Biopsy for liver cancer: How to balance research needs with evidence-based clinical practice. Hepatology, 2015, 61, 433-436.	7.3	36
111	Results of laparoscopic radiofrequency ablation for HCC. Could the location of the tumour influence a complete response to treatment? A single European centre experience. Hpb, 2015, 17, 387-393.	0.3	44
112	Systemic Treatment: Expecting Further Success. Digestive Diseases, 2015, 33, 590-597.	1.9	1
113	Liver cancer: Approaching a personalized care. Journal of Hepatology, 2015, 62, S144-S156.	3.7	239
114	Surgical resection for hepatocellular carcinoma: Moving from what can be done to what is worth doing. Hepatology, 2015, 62, 340-342.	7.3	22
115	Intermediate-stage HCC"upfront resection can be feasible. Nature Reviews Clinical Oncology, 2015, 12, 295-295.	27.6	7
116	Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US. Radiology, 2015, 275, 698-707.	7.3	115
117	Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncology, The, 2015, 16, 1344-1354.	10.7	809
118	Reply to: "Poor contrast enhanced ultrasonography! There is no limit to its decline in the diagnosis of hepatocellular carcinoma on cirrhosis!"™. Journal of Hepatology, 2015, 62, 1453-1454.	3.7	0
119	Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery. Nature Reviews Clinical Oncology, 2015, 12, 10-10.	27.6	20
120	Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules <2cm. Journal of Hepatology, 2015, 62, 150-155.	3.7	46
121	Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta-analysis. Hepatology, 2015, 61, 526-536.	7.3	286
122	LI-RADS (Liver Imaging Reporting and Data System): Summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. Hepatology, 2015, 61, 1056-1065.	7.3	412
123	Systemic Therapy for Hepatocellular Carcinoma: The Issue of Treatment Stage Migration and Registration of Progression Using the BCLC-Refined RECIST. Seminars in Liver Disease, 2014, 34, 444-455.	3.6	112
124	Treatment of Hepatocellular Carcinoma. Digestive Diseases, 2014, 32, 554-563.	1.9	33
125	Hepatocellular Carcinoma: Paving the Road for Further Developments. Seminars in Liver Disease, 2014, 34, 361-362.	3.6	1
126	Hepatocellular carcinoma: clinical frontiers and perspectives. Gut, 2014, 63, 844-855.	12.1	1,180



#	ARTICLE	IF	CITATIONS
127	The challenges of novel contrast agents for the imaging diagnosis of hepatocellular carcinoma. <i>Hepatology International</i> , 2014, 8, 4-6.	4.2	2
128	Liver Transplantation for Hepatocellular Carcinoma in HCV-Infected Patients. , 2014, , 77-93.		0
129	Selective Inhibition of Hepatitis C Virus Infection by Hydroxyzine and Benztropine. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3451-3460.	3.2	19
130	Systemic treatment. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 921-935.	2.4	9
131	Hepatocellular carcinoma: Current state of the art in diagnosis and treatment. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 751.	2.4	11
132	Treatment of intermediate-stage hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 525-535.	27.6	377
133	<i>Hepatic Oncology</i>: a journal for all stakeholders in liver cancer management. <i>Hepatic Oncology</i> , 2014, 1, 1-1.	4.2	0
134	FOLFOX-4 vs. doxorubicin for hepatocellular carcinoma: Could a negative result be accepted as positive?. <i>Journal of Hepatology</i> , 2014, 61, 164-165.	3.7	3
135	Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. <i>Journal of Hepatology</i> , 2014, 61, 318-324.	3.7	203
136	Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial. <i>Hepatic Oncology</i> , 2014, 1, 181-188.	4.2	16
137	STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC). <i>Journal of Clinical Oncology</i> , 2014, 32, 4006-4006.	1.6	38
138	RESORCE: An ongoing randomized, double-blind, phase III trial of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing on sorafenib (SOR).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS4156-TPS4156.	1.6	0
139	A DNA methylation signature associated with the epigenetic repression of glycine N-methyltransferase in human hepatocellular carcinoma. <i>Journal of Molecular Medicine</i> , 2013, 91, 939-950.	3.9	29
140	Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design. <i>Hepatology</i> , 2013, 58, 2023-2031.	7.3	217
141	Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study. <i>European Journal of Cancer</i> , 2013, 49, 3412-3419.	2.8	218
142	Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2013, 59, 1271-1277.	3.7	66
143	Corrigendum to: "FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC3 program" [Hepatology 2011;54:227-235]. <i>Journal of Hepatology</i> , 2013, 59, 914.	3.7	1
144	The Size of the Problem: Clinical Algorithms. <i>Digestive Diseases</i> , 2013, 31, 95-103.	1.9	5

#	ARTICLE	IF	CITATIONS
145	Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: A randomized study. <i>Journal of Hepatology</i> , 2013, 58, 452-459.	3.7	7
146	Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3509-3516.	1.6	544
147	Treatment of Hepatocellular Carcinoma with Radioembolization: Gathering Assumptions for Trial Design. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 1197-1199.	0.5	2
148	Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes. <i>Gastroenterology</i> , 2013, 144, 829-840.	1.3	438
149	New OPTN/UNOS Policy for Liver Transplant Allocation: Standardization of Liver Imaging, Diagnosis, Classification, and Reporting of Hepatocellular Carcinoma. <i>Radiology</i> , 2013, 266, 376-382.	7.3	334
150	Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET's Letter. <i>Clinical Cancer Research</i> , 2013, 19, 4290-4290.	7.0	12
151	If portal hypertension predicts outcome in cirrhosis, why should this not be the case after surgical resection?. <i>Liver International</i> , 2013, 33, 1454-1456.	3.9	5
152	Metiv-HCC: A phase III clinical trial evaluating tivantinib (ARQ 197), a MET inhibitor, versus placebo as second-line in patients (pts) with MET-high inoperable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS4159-TPS4159.	1.6	6
153	Regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing following sorafenib: An ongoing randomized, double-blind, phase III trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS4163-TPS4163.	1.6	1
154	Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3 61, 1481-1487.	12.1	154
155	Screening for Liver Cancer: The Rush to Judgment. <i>Annals of Internal Medicine</i> , 2012, 157, 300.	3.9	4
156	Management of HCC. <i>Journal of Hepatology</i> , 2012, 56, S75-S87.	3.7	509
157	Hepatocellular carcinoma. <i>Lancet, The</i> , 2012, 379, 1245-1255.	13.7	3,897
158	Hepatocellular carcinoma - Authors' reply. <i>Lancet, The</i> , 2012, 380, 470-471.	13.7	29
159	Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib. <i>Clinical Cancer Research</i> , 2012, 18, 4997-5007.	7.0	251
160	Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. <i>Journal of Hepatology</i> , 2012, 56, 103-108.	3.7	142
161	Chemoembolization for intermediate HCC: Is there proof of survival benefit?. <i>Journal of Hepatology</i> , 2012, 56, 984-986.	3.7	99
162	EASL's EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 56, 908-943.	3.7	5,214

#	ARTICLE	IF	CITATIONS
163	Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. <i>Journal of Hepatology</i> , 2012, 56, 1080-1088.	3.7	109
164	Non-invasive diagnosis of hepatocellular carcinoma $\leq 2$ cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. <i>Journal of Hepatology</i> , 2012, 56, 1317-1323.	3.7	159
165	Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. <i>Journal of Hepatology</i> , 2012, 56, 1330-1335.	3.7	436
166	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. <i>Journal of Hepatology</i> , 2012, 57, 821-829.	3.7	736
167	Screening for hepatocellular carcinoma: The rationale for the American Association for the Study of Liver Diseases recommendations. <i>Hepatology</i> , 2012, 56, 793-796.	7.3	129
168	Biomarkers for early diagnosis of hepatocellular carcinoma. <i>Lancet Oncology</i> , The, 2012, 13, 750-751.	10.7	102
169	Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2012, 18, 2290-2300.	7.0	503
170	Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA154-LBA154.	1.6	76
171	Saudi Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: Technical Review and Practice Guidelines. <i>Annals of Saudi Medicine</i> , 2012, 32, 174-199.	1.1	26
172	Diagnosis of Early Hepatocellular Carcinoma: Ideal Goal, But Not Yet There. <i>Gastroenterology</i> , 2011, 140, 358-360.	1.3	2
173	Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2011, 140, 1501-1512.e2.	1.3	389
174	MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517a. <i>Gastroenterology</i> , 2011, 140, 1618-1628.e16.	1.3	205
175	Maintenance Therapy With Peginterferon Alfa-2b Does Not Prevent Hepatocellular Carcinoma in Cirrhotic Patients With Chronic Hepatitis C. <i>Gastroenterology</i> , 2011, 140, 1990-1999.	1.3	102
176	The Search for an Effective Partner for Sorafenib: The Failure of Doxorubicin. <i>Gastroenterology</i> , 2011, 140, 1687-1688.	1.3	1
177	FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC3 program. <i>Journal of Hepatology</i> , 2011, 54, 227-235.	3.7	19
178	Gene-expression signature of vascular invasion in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2011, 55, 1325-1331.	3.7	133
179	Management of hepatocellular carcinoma: An update. <i>Hepatology</i> , 2011, 53, 1020-1022.	7.3	7,111
180	Liver cancer: Still a long way to go. <i>Hepatology</i> , 2011, 54, 1-2.	7.3	37

#	ARTICLE	IF	CITATIONS
181	Clinical decision making and research in hepatocellular carcinoma: Pivotal role of imaging techniques. <i>Hepatology</i> , 2011, 54, 2238-2244.	7.3	101
182	Diagnostic Imaging and Biopsy Use Among Elderly Medicare Beneficiaries With Hepatocellular Carcinoma. <i>Journal of Oncology Practice</i> , 2011, 7, 155-160.	2.5	9
183	Hepatocellular Carcinoma (HCC). <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 239-245.	2.2	251
184	Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 1239-1244.	1.6	18
185	Medical treatments: in association or alone, their roles and their future perspectives. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2010, 17, 420-421.	2.6	1
186	Multifaceted perspective of the waiting list for liver transplantation: The value of pharmacokinetic models. <i>Hepatology</i> , 2010, 51, 12-15.	7.3	25
187	A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. <i>Hepatology</i> , 2010, 51, 1274-1283.	7.3	374
188	Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. <i>Hepatology</i> , 2010, 51, 2020-2029.	7.3	268
189	Reply:. <i>Hepatology</i> , 2010, 52, 1516-1517.	7.3	0
190	Two Decades of Advances in Hepatocellular Carcinoma Research. <i>Seminars in Liver Disease</i> , 2010, 30, 001-002.	3.6	21
191	Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects. <i>Seminars in Liver Disease</i> , 2010, 30, 061-074.	3.6	945
192	Treatment of early hepatocellular carcinoma: Towards personalized therapy. <i>Digestive and Liver Disease</i> , 2010, 42, S242-S248.	0.9	31
193	Failure of Interferon to Prevent Disease Progression and Liver Cancer in Hepatitis C Virus Infection: Proof of Absence or Absence of Proof?. <i>Gastroenterology</i> , 2010, 138, 777-779.	1.3	2
194	MicroRNA Analysis for Outcome Prediction in Hepatitis B Virus-Related Liver Cancer. <i>Gastroenterology</i> , 2010, 138, 1624-1626.	1.3	3
195	Ablation for hepatocellular carcinoma: Is there need to have a winning technique?. <i>Journal of Hepatology</i> , 2010, 52, 310-312.	3.7	16
196	IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. <i>Journal of Hepatology</i> , 2010, 52, 550-559.	3.7	211
197	Treating hepatitis C in patients with cirrhosis: The effort is worth it. <i>Journal of Hepatology</i> , 2010, 52, 624-626.	3.7	12
198	A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. <i>BMC Cancer</i> , 2010, 10, 209.	2.6	174

#	ARTICLE	IF	CITATIONS
199	Testing Molecular Therapies in Hepatocellular Carcinoma: The Need for Randomized Phase II Trials. <i>Journal of Clinical Oncology</i> , 2009, 27, 833-835.	1.6	32
200	East meets the West—portal pressure predicts outcome of surgical resection for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2009, 6, 14-15.	1.7	15
201	Antiangiogenic therapy: Not just for cancer anymore?. <i>Hepatology</i> , 2009, 49, 1066-1068.	7.3	30
202	Cholangiocarcinoma in cirrhosis: Absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. <i>Hepatology</i> , 2009, 50, 791-798.	7.3	253
203	Reply:. <i>Hepatology</i> , 2009, 50, 1316-1317.	7.3	0
204	The need for novel and interesting data in liver cancer research. <i>Hepatology</i> , 2009, 50, 1690-1691.	7.3	1
205	Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma. <i>Cancer</i> , 2009, 115, 616-623.	4.1	403
206	New drugs for the treatment of hepatocellular carcinoma. <i>Liver International</i> , 2009, 29, 148-158.	3.9	22
207	Angiogenesis in liver disease. <i>Journal of Hepatology</i> , 2009, 50, 604-620.	3.7	510
208	Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. <i>Journal of Hepatology</i> , 2009, 51, 725-733.	3.7	206
209	Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy. <i>Gastroenterology</i> , 2009, 136, 1618-1628.e2.	1.3	225
210	Î±-Fetoprotein for Hepatocellular Carcinoma Diagnosis: The Demise of a Brilliant Star. <i>Gastroenterology</i> , 2009, 137, 26-29.	1.3	89
211	To Expand or Not to Expand the Criteria for Hepatocellular Carcinoma Transplantation: Is Downstaging the Answer?. <i>Gastroenterology</i> , 2009, 137, 375-376.	1.3	3
212	Sorafenib for Hepatocellular Carcinoma: Global Validation. <i>Gastroenterology</i> , 2009, 137, 1171-1173.	1.3	5
213	Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. <i>Lancet Oncology</i> , The, 2009, 10, 35-43.	10.7	1,920
214	Sunitinib and the benefits of a negative study. <i>Lancet Oncology</i> , The, 2009, 10, 743-744.	10.7	11
215	Major achievements in hepatocellular carcinoma. <i>Lancet</i> , The, 2009, 373, 614-616.	13.7	275
216	Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. <i>Hepatology</i> , 2008, 47, 97-104.	7.3	884

#	ARTICLE	IF	CITATIONS
217	Liver cancer: An evolving challenge reaching research maturity. <i>Hepatology</i> , 2008, 47, 1103-1104.	7.3	3
218	Reply:. <i>Hepatology</i> , 2008, 47, 2146-2147.	7.3	8
219	Molecular targeted therapies in hepatocellular carcinoma. <i>Hepatology</i> , 2008, 48, 1312-1327.	7.3	899
220	Sorafenib in Advanced Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2008, 359, 378-390.	27.0	12,004
221	Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2008, 135, 1972-1983.e11.	1.3	644
222	Focal Gains of <i>VEGFA</i> and Molecular Classification of Hepatocellular Carcinoma. <i>Cancer Research</i> , 2008, 68, 6779-6788.	0.9	589
223	Novel advancements in the management of hepatocellular carcinoma in 2008. <i>Journal of Hepatology</i> , 2008, 48, S20-S37.	3.7	739
224	Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma. <i>Journal of the National Cancer Institute</i> , 2008, 100, 698-711.	6.3	1,545
225	Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2008, 359, 1995-2004.	27.0	1,148
226	Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. <i>Journal of Hepatology</i> , 2007, 46, 645-654.	3.7	75
227	Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics. <i>Journal of Hepatology</i> , 2007, 46, 474-481.	3.7	864
228	Reply: Chemoembolization with drug eluting beads in HCC. <i>Journal of Hepatology</i> , 2007, 47, 159.	3.7	1
229	Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. <i>Hepatology</i> , 2007, 45, 938-947.	7.3	632
230	Locoregional treatment for hepatocellular carcinoma: From clinical exploration to robust clinical data, changing standards of care. <i>Hepatology</i> , 2007, 47, 5-7.	7.3	17
231	Transarterial chemoembolization for patients with hepatocellular carcinoma. <i>Hepatology Research</i> , 2007, 37, S230-7.	3.4	14
232	Distinct cellular responses differentiating alcohol- and hepatitis C virus-induced liver cirrhosis. <i>Virology Journal</i> , 2006, 3, 98.	3.4	28
233	A Molecular Signature to Discriminate Dysplastic Nodules From Early Hepatocellular Carcinoma in HCV Cirrhosis. <i>Gastroenterology</i> , 2006, 131, 1758-1767.	1.3	379
234	Hepatocellular carcinoma in the United States. Lessons from a population-based study in Medicare recipients. <i>Journal of Hepatology</i> , 2006, 44, 8-10.	3.7	13

#	ARTICLE	IF	CITATIONS
235	New aspects of diagnosis and therapy of hepatocellular carcinoma. <i>Oncogene</i> , 2006, 25, 3848-3856.	5.9	143
236	Is microbubble-enhanced ultrasonography sufficient for assessment of response to percutaneous treatment in patients with early hepatocellular carcinoma?. <i>European Radiology</i> , 2006, 16, 2454-2462.	4.5	99
237	Treatment of hepatocellular carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 60, 89-98.	4.4	140
238	Hepatocellular carcinoma in the setting of liver transplantation. <i>Liver Transplantation</i> , 2006, 12, 1028-1036.	2.4	28
239	Diagnosis and staging of hepatocellular carcinoma prior to transplantation: Expertise or failure. <i>Liver Transplantation</i> , 2006, 12, 1445-1447.	2.4	5
240	Expanded Criteria for Hepatocellular Carcinoma Through Down-Staging Prior to Liver Transplantation: Not Yet There. <i>Seminars in Liver Disease</i> , 2006, 26, 248-253.	3.6	29
241	Liver transplantation in hepatocellular carcinoma. <i>Transplant International</i> , 2005, 18, 278-282.	1.6	27
242	Ecografía con contraste de segunda generación (SonoVue®) en la valoración del tratamiento percutáneo del carcinoma hepatocelular. Comparación con la TC multifásica. <i>Radiología</i> , 2005, 47, 79-85.	0.5	1
243	Management of hepatocellular carcinoma. <i>Hepatology</i> , 2005, 42, 1208-1236.	7.3	5,426
244	Clinical Management of Hepatic Malignancies: Ferucarbotran-Enhanced Magnetic Resonance Imaging Versus Contrast-Enhanced Spiral Computed Tomography. <i>Digestive Diseases and Sciences</i> , 2005, 50, 533-537.	2.3	19
245	Prognostic Prediction in Patients with Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2005, 25, 171-180.	3.6	80
246	Applicability of adult-to-adult living donor liver transplantation. <i>Journal of Hepatology</i> , 2005, 43, 104-109.	3.7	30
247	Diagnosis of Small HCC. <i>Gastroenterology</i> , 2005, 129, 1364.	1.3	28
248	Unresectable Hepatocellular Carcinoma: Meta-Analysis of Arterial Embolization [letter]. <i>Radiology</i> , 2004, 230, 300-302.	7.3	23
249	Focus on hepatocellular carcinoma. <i>Cancer Cell</i> , 2004, 5, 215-219.	16.8	523
250	Prognostic prediction in HCC: Did anybody expect it to be easy?. <i>Hepatology</i> , 2004, 39, 551-552.	7.3	14
251	Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. <i>Hepatology</i> , 2004, 40, 1047-1052.	7.3	142
252	Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. <i>Hepatology</i> , 2004, 40, 1352-1360.	7.3	409



#	ARTICLE	IF	CITATIONS
253	The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transplantation, 2004, 10, S115-S120.	2.4	616
254	High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: An indication for salvage liver transplantation. Liver Transplantation, 2004, 10, 1294-1300.	2.4	263
255	Selection of candidates with HCC for transplantation in the MELD era. Liver Transplantation, 2004, 10, S4-S9.	2.4	39
256	Preoperative evaluation of biliary anatomy in adult live liver donors with volumetric mangafodipir trisodium enhanced magnetic resonance cholangiography. Liver Transplantation, 2004, 10, 1391-1397.	2.4	40
257	Chemoembolization for hepatocellular carcinoma. Gastroenterology, 2004, 127, S179-S188.	1.3	504
258	Orthotopic Implantation of Human Hepatocellular Carcinoma in Mice. Clinical Cancer Research, 2004, 10, 2150-2157.	7.0	25
259	Abdominal drainage after liver resection for hepatocellular carcinoma in cirrhotic patients: a randomized controlled study. Hepato-Gastroenterology, 2004, 51, 536-40.	0.5	25
260	Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology, 2003, 37, 429-442.	7.3	2,646
261	HCC surveillance: Who is the target population?. Hepatology, 2003, 37, 507-509.	7.3	46
262	Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision. Liver Transplantation, 2003, 9, 700-702.	2.4	99
263	MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: An explant correlation. Hepatology, 2003, 38, 1034-1042.	7.3	401
264	Contrast-enhanced power Doppler sonography and helical computed tomography for assessment of vascularity of small hepatocellular carcinomas before and after percutaneous ablation. Journal of Clinical Ultrasound, 2003, 31, 119-128.	0.8	28
265	Hepatitis C virus and liver disease: Global transcriptional profiling and identification of potential markers. Hepatology, 2003, 38, 1458-1467.	7.3	81
266	Treatment Strategies for Hepatocellular Carcinoma in Cirrhosis. Journal of Gastrointestinal Surgery, 2003, 7, 401-411.	1.7	20
267	p27Kip1 is an independent predictor of recurrence after surgical resection in patients with small hepatocellular carcinoma. Journal of Hepatology, 2003, 38, 591-597.	3.7	38
268	Hepatitis B virus and hepatocellular carcinoma. Journal of Hepatology, 2003, 39, 59-63.	3.7	87
269	Hepatocellular carcinoma. Lancet, The, 2003, 362, 1907-1917.	13.7	3,886
270	Treatment of hepatocellular carcinoma: is there an optimal strategy?. Cancer Treatment Reviews, 2003, 29, 99-104.	7.7	61

#	ARTICLE	IF	CITATIONS
271	MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: An explant correlation. <i>Hepatology</i> , 2003, 38, 1034-1042.	7.3	142
272	Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma. <i>Cancer Research</i> , 2003, 63, 859-64.	0.9	120
273	Interferon for the prevention of hepatocellular carcinoma. <i>Perspectives in Medical Virology</i> , 2002, 6, 151-159.	0.1	0
274	Prognostic Assessment and Evaluation of the Benefits of Treatment. <i>Journal of Clinical Gastroenterology</i> , 2002, 35, S138-S142.	2.2	28
275	Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. <i>Lancet</i> , The, 2002, 359, 1734-1739.	13.7	3,172
276	Expected developments in hepatology. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2002, 16, 957-970.	2.4	6
277	Prognostic prediction and treatment strategy in hepatocellular carcinoma. <i>Hepatology</i> , 2002, 35, 519-524.	7.3	1,003
278	Prognosis of hepatocellular carcinoma. <i>Hepato-Gastroenterology</i> , 2002, 49, 7-11.	0.5	23
279	Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference. <i>Journal of Hepatology</i> , 2001, 35, 421-430.	3.7	3,959
280	Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective. <i>Hepatology</i> , 2001, 33, 1073-1079.	7.3	242
281	Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. <i>Hepatology</i> , 2001, 33, 1124-1129.	7.3	698
282	High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-related cirrhosis. <i>Hepatology</i> , 2001, 34, 158-167.	7.3	44
283	Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. <i>Hepatology</i> , 2000, 31, 54-58.	7.3	242
284	Early diagnosis and treatment of hepatocellular carcinoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2000, 14, 991-1008.	2.4	45
285	Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. <i>Hepatology</i> , 2000, 31, 1019-1021.	7.3	413
286	Prospective Validation of the Cancer of the Liver Italian Program (CLIP) Score: A New Prognostic System for Patients With Cirrhosis and Hepatocellular Carcinoma. <i>Hepatology</i> , 2000, 32, 679-680.	7.3	140
287	Nonsurgical treatment of hepatocellular carcinoma. <i>Liver Transplantation</i> , 2000, 6, s11-s15.	2.4	24
288	THE CURRENT STATUS OF LIVER TRANSPLANTATION FOR PRIMARY HEPATIC MALIGNANCY. <i>Clinics in Liver Disease</i> , 2000, 4, 591-605.	2.1	28

#	ARTICLE	IF	CITATIONS
289	Hepatocellular carcinoma and the art of prognostication. <i>Journal of Hepatology</i> , 2000, 33, 1006-1008.	3.7	18
290	Prevalence and prognostic value of hepatocellular carcinoma in cirrhotic patients presenting with spontaneous bacterial peritonitis. <i>Journal of Hepatology</i> , 2000, 33, 423-429.	3.7	29
291	Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification. <i>Seminars in Liver Disease</i> , 1999, 19, 329-338.	3.6	3,350
292	Locoregional treatments for hepatocellular carcinoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 1999, 13, 611-622.	2.4	20
293	Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials. <i>Hepatology</i> , 1999, 29, 62-67.	7.3	1,044
294	Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation. <i>Hepatology</i> , 1999, 30, 1434-1440.	7.3	1,869
295	Infection with a novel human DNA virus (TTV) has no pathogenic significance in patients with liver diseases. <i>Journal of Hepatology</i> , 1999, 30, 1028-1034.	3.7	67
296	Liver transplantation for small hepatocellular carcinoma: The tumor-node-metastasis classification does not have prognostic power. <i>Hepatology</i> , 1998, 27, 1572-1577.	7.3	357
297	Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution. <i>Hepatology</i> , 1998, 27, 1578-1583.	7.3	482
298	Tumor necrosis factor primes hepatocytes for DNA replication in the rat. <i>Hepatology</i> , 1998, 28, 1226-1234.	7.3	259
299	Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action. <i>Journal of Hepatology</i> , 1998, 29, 173-183.	3.7	145
300	Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma. <i>Journal of Hepatology</i> , 1997, 27, 959-965.	3.7	120
301	Hepatocellular Carcinoma and Cirrhosis. <i>Annals of Surgery</i> , 1996, 223, 297-302.	4.2	210
302	Treatment of hepatocellular carcinoma with tamoxifen: A double-blind placebo-controlled trial in 120 patients. <i>Gastroenterology</i> , 1995, 109, 917-922.	1.3	191
303	Transarterial embolization for hepatocellular carcinoma. Antibiotic prophylaxis and clinical meaning of postembolization fever. <i>Journal of Hepatology</i> , 1995, 22, 410-415.	3.7	95
304	Androgen receptors in hepatocellular carcinoma and surrounding liver: relationship with tumor size and recurrence rate after surgical resection. <i>Journal of Hepatology</i> , 1995, 22, 616-622.	3.7	35
305	c-met mRNA overexpression in human hepatocellular carcinoma. <i>Hepatology</i> , 1994, 19, 88-91.	7.3	119
306	Phase II study of transarterial embolization in european patients with hepatocellular carcinoma: Need for controlled trials. <i>Hepatology</i> , 1994, 20, 643-650.	7.3	83

#	ARTICLE	IF	CITATIONS
307	nm23-H1 Expression and disease recurrence after surgical resection of small hepatocellular carcinoma. <i>Gastroenterology</i> , 1994, 107, 486-491.	1.3	27
308	c-met mRNA overexpression in human hepatocellular carcinoma. <i>Hepatology</i> , 1994, 19, 88-91.	7.3	7
309	Phase II study of transarterial embolization in European patients with hepatocellular carcinoma: Need for controlled trials. <i>Hepatology</i> , 1994, 20, 643-650.	7.3	2
310	Treatment of small hepatocellular carcinoma in cirrhotic patients: A cohort study comparing surgical resection and percutaneous ethanol injection. <i>Hepatology</i> , 1993, 18, 1121-1126.	7.3	305
311	Sex hormone receptors in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 1993, 17, 187-191.	3.7	59
312	Surgical resection and survival in western patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 1992, 15, 350-355.	3.7	28
313	Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. <i>Hepatology</i> , 1992, 16, 353-357.	7.3	273
314	Diarrhea as a presenting symptom of hepatocellular carcinoma. <i>Digestive Diseases and Sciences</i> , 1990, 35, 681-685.	2.3	18
315	Prognostic factors of hepatocellular carcinoma in the west: A multivariate analysis in 206 patients. <i>Hepatology</i> , 1990, 12, 753-760.	7.3	229
316	Natural history of hepatocellular carcinoma in Spain. <i>Journal of Hepatology</i> , 1990, 10, 311-317.	3.7	122
317	Diagnostic accuracy of fine-needle aspiration biopsy in patients with hepatocellular carcinoma. <i>Digestive Diseases and Sciences</i> , 1989, 34, 1765-1769.	2.3	54
318	Î²-Blockade with propranolol and hepatic artery blood flow in patients with cirrhosis. <i>Hepatology</i> , 1989, 10, 269-272.	7.3	22
319	PREVALENCE OF ANTIBODIES TO HEPATITIS C VIRUS IN SPANISH PATIENTS WITH HEPATOCELLULAR CARCINOMA AND HEPATIC CIRRHOSIS. <i>Lancet, The</i> , 1989, 334, 1004-1006.	13.7	693
320	Endoscopic measurement of variceal pressure in cirrhosis: Correlation with portal pressure and variceal hemorrhage. <i>Gastroenterology</i> , 1989, 96, 873-880.	1.3	82
321	Endoscopic Measurement of Variceal Pressure in Cirrhosis: Correlation With Portal Pressure and Variceal Hemorrhage. <i>Gastroenterology</i> , 1989, 96, 873-880.	1.3	154
322	Esophageal dysfunction in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 1988, 7, 362-367.	3.7	8
323	Effects of metoclopramide and domperidone on azygos venous blood flow in patients with cirrhosis and portal hypertension. <i>Hepatology</i> , 1986, 6, 1244-1247.	7.3	38
324	Temporal relationship between hyperaldosteronism, sodium retention and ascites formation in rats with experimental cirrhosis. <i>Hepatology</i> , 1985, 5, 245-250.	7.3	117

#	ARTICLE	IF	CITATIONS
325	Measurement of azygos venous blood flow in the evaluation of portal hypertension in patients with cirrhosis. <i>Journal of Hepatology</i> , 1985, 1, 125-139.	3.7	179
326	Comparison of Intravenous Somatostatin and Vasopressin Infusions in Treatment of Acute Variceal Hemorrhage. <i>Hepatology</i> , 1984, 4, 442-446.	7.3	243
327	Effects of Propranolol on Azygos Venous Blood Flow and Hepatic and Systemic Hemodynamics in Cirrhosis. <i>Hepatology</i> , 1984, 4, 1200-1205.	7.3	299
328	Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension. <i>Hepatology</i> , 1982, 2, 757-762.	7.3	233
329	Management of Hepatocellular Cancer. , 0, , 740-754.		0